drugset / Trial / NCT00675103
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry. This study is limited to four study centers in the US.
Timeline
- Start
- 2008-05
- Primary completion
- 2009-01
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegloticase | Protein / enzyme biologic | 8 mg | Intravenous |